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Abstract. Background: Apomorphine infusion therapy remains under-used and there are no comparative studies of motor and
non-motor effects of apomorphine infusion.
Methods: In this paper we report preliminary results from an ongoing clinical observational “real life” surveillance-based
study focused on effects of this therapy on non-motor symptoms and health-related quality of life in a group of patients on
apomorphine.
Results: Apomorphine infusion led to highly significant improvements in UPDRS 3 (p = 0.0003), UPDRS 4 (p = 0.0003),
PDQ-8 (Parkinson’s disease questionnaire, p = 0.001) and NMSS total (non motor symptoms scale, p = 0.0003). Furthermore,
apomorphine was tolerated in patients with visual hallucinations, illusions and paranoid ideations while significant improvement
in specific non-motor symptoms such as hyperhidrosis, nocturia, urgency of micturition, and fatigue was recorded. Levodopa
equivalent dose decreased significantly (1077.81 ± 446.26 to 458.75 ± 282.29, p < 0.0001) and a large effect size of intervention
was noted. In an untreated group no such improvement was noted. The number needed to treat (NNT) for improvement >1 SEM
in the Apo group was calculated and was lower than 2 for >1 SEM improvement of UPDRS 3, NMSS, and PDQ-8 total scores.
Conclusions: This pilot observational study suggests that non-motor effects are evident with apomorphine therapy and patients
suitable for apomorphine deteriorate in the absence of therapy.
∗Correspondence to: Prof. K. Ray Chaudhuri, Department of
Neurology, King’s College Hospital, Denmark Hill, SE5 9RS
London, UK. E-mail: chaudhuriray@hotmail.com.
INTRODUCTION
Subcutaneous administration of apomorphine (Apo)
has been used as treatment for advanced Parkin-
son’s disease (PD) with refractory on-off periods and
dyskinesias and is nationally recommended in many
ISSN 1877-7171/11/$27.50 © 2011 – IOS Press and the authors. All rights reserved
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countries [1–10]. We have reported the beneficial effect
of apomorphine infusion on aspects of non-motor
symptoms (NMS) of PD as assessed by the validated
PD NMS scale (NMSS) [11–14]. There are no studies
comparing non-motor effects of apomorphine infusion
in two groups of PD patients deemed suitable for apo-
morphine therapy yet where one group is treated by
conventional (oral and patch therapy) treatment only
because of local funding issues.
PATIENTS AND METHODS
Between 2008–2009, 17 PD patients (all satisfy-
ing the UK PD brain Bank criteria) [15] with severe
dyskinesias (as rated by patients, carers and clinician)
and on-off fluctuations unresponsive to changes in
existing therapy were started on apomorphine infu-
sion (12–16 hrs/day) and followed up in centres across
Europe. All had baseline assessment (“7 to 10 days
pre-treatment” of motor function (Unified Parkinson’s
Disease Rating Scale, UPDRS 3 and 4) [16], Hoehn
and Yahr staging (HY) [17], Non-Motor Symptoms
Scale (NMSS) [13, 14] and health-related quality of life
(HRQoL) (Parkinson’s disease questionnaire, PDQ-8)
[18]. Follow-up assessments were carried out in a man-
ner similar to that recently reported [8]. For analysis,
baseline data was compared to the last available follow-
up visit of each patient at “on” stage.
Seventeen PD patients were selected for comparison
(C) as these patients were not funded for apomorphine.
These patients also had severe dyskinesias and on-off
fluctuations unresponsive to further modifications in
their existing therapy. These patients were followed
up while on best conventional therapy using the same
clinical protocol. As this was a clinically dictated study,
matching for C and Apo cases from individual centres
was not possible.
As this was a clinical observational surveillance
audit based study, with a licensed drug for the approved
indication specific ethical approval was not required,
as confirmed by written statements from the Bispeb-
jerg Hospital, Copenhagen ethics committee and ethics
committee in Donauspital, Vienna. Use of NMSS
methodology was approved for use by the ethics com-
mittee of the University Hospital of Lewisham, Kings
College Hospital, Madrid, and Bremerhaven.
Statistical analysis
Chi-squared and Fisher’s exact tests were used
for comparison of proportions, while non-parametric
tests were applied for ordinal and continuous vari-
ables. Multiple comparisons were corrected by the
Benjamini-Hochberg method [19] and for the associa-
tion of changes Spearman rank correlation coefficient
was used [20]. For each measure, the relative change
[RC = mean (testT2 – testT1) × 100/mean testT1)], the
effect size [ES = mean (testT2 – testT1)/SD testT1]
and the standardized response mean [SRM = mean
(testT2 – testT1)/SD (testT2 – testT1)] were calculated to
determine the magnitude of change. For both effect
size indices, ES and SRM, the standard values are:
0.20–0.49, Small effect; 0.50–0.79, Moderate effect;
and ≥0.80, Large effect [21–23]. The number needed
to treat (NNT) for improvement >1 SEM in the Apo
group was calculated [24–27].
RESULTS
Seventeen Apo (mean age 59.5 ± 11.7 yrs, disease
duration 12.05 ± 4 yrs, median HY score 4) were
started on apomorphine infusion using a standardised
local initiation protocol and the data compared to 17 C
patients (mean age 66.4 ± 7.0 yrs, disease duration
13.23 ± 4.7 yrs, median HY score 3.9) over a period of
12.5 ± 11.5months. At baseline, there were no signif-
icant differences between Apo and C with respect to
age, gender and PD duration and both groups were on
comparable levodopa and dopamine agonist treatments
and had resistant on-off fluctuations and dyskinesias.
The levodopa equivalent (LDE) doses in both groups
were similar between Apo (1077.81 ± 446.26 mg) and
C (1028.18 ± 388.76 mg) at baseline. At baseline, the
UPDRS 3, NMSS-Total and PDQ-8 showed signif-
icant differences between C and Apo group, the C
group being lower in scores (indicative of better state).
During follow-up, the C group showed worsening in
PDQ-8 (Table 1) while Apo showed highly signifi-
cant improvements in UPDRS 3 (p = 0.0003), UPDRS
4 (p = 0.0003) PDQ-8 (p = 0.001) and NMSS total
(p = 0.0003, Table 2). The LDE increased significantly
during follow-up in the C group (1028.18 ± 388.76
to 1154.54 ± 407.09 mg, p = 0.001) while in the
Apo, LDE decreased significantly (1077.81 ± 446.26
to 458.75 ± 282.29, p < 0.0001) with improvement
affecting more than 90% of patients and large effect
size. In the Apo group, moderate to large effect size
on the NMSS domains of sleep, mood/apathy, atten-
tion, gastrointestinal, urinary, sexual, and miscellany
was evident (Table 3).
In the Apo group, there was a high correlation
between change in UPDRS 3 and PDQ-8 (rs = 0.85)
and moderate between change in NMSS and PDQ-8
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Table 1
Changes following Apomorphine infusion and continuing conventional therapy (comparator) in motor,
non-motor, and quality of life dimensions
Control Apomorphine
Baseline Follow-up p Baseline Follow-up p
UPDRS-Motor exam 20.06 (9.68) 19.35 (12.80) 0.69 36.94 (11.42) 15.35 (8.21) 0.0003
UPDRS-Complications 7.93 (5.43) 7.00 (4.46) 0.48 10.00 (6.43) 3.53 (3.52) 0.0003
NMSS-Cardiovascular 1.29 (2.97) 1.18 (2.90) 0.45 4.65 (5.63) 2.76 (3.51) 0.03
Sleep 12.29 (9.58) 12.06 (9.32) 0.90 22.06 (11.47) 10.71 (9.63) 0.0003
Mood/apathy 8.35 (10.33) 8.06 (8.78) 0.79 22.76 (19.85) 11.29 (13.04) 0.0005
Perceptual 2.23 (5.03) 2.59 (6.26) 0.90 4.59 (6.92) 1.88 (3.35) 0.04
Attention 6.00 (8.40) 7.18 (7.76) 0.16 12.82 (9.62) 8.71 (7.75) 0.006
Gastrointestinal 5.94 (5.97) 7.12 (6.49) 0.24 7.35 (7.35) 4.41 (5.11) 0.002
Urinary 4.29 (3.57) 6.23 (4.26) 0.06 10.70 (8.93) 5.71 (6.72) 0.001
Sexual 3.12 (6.58) 3.29 (6.12) 0.97 2.53 (5.96) 2.00 (3.94) 0.42
Miscellany 4.12 (5.67) 4.29 (5.55) 0.61 18.47 (14.54) 9.47 (9.70) 0.0003
NMSS-Total score 47.65 (43.40) 52.00 (37.65) 0.22 105.94 (65.43) 56.94 (45.39) 0.0003
PDQ-8 35.84 (23.10) 44.85 (17.57) 0.02 55.70 (19.80) 32.35 (21.54) 0.001
Benjamini-Hochberg correction: p < 0.027; UPDRS: Unified Parkinson’s Disease Rating Scale; NMSS: Non-
Motor Symptoms Scale; PDQ-8: Parkinson’s Disease Questionnaire-8 items.
(rs = 0.44). The NNT was lower than 2 for >1 SEM
improvement of UPDRS 3, NMSS, and PDQ-8 total
scores. The average NNT for NMSS domains was 3.95
(Table 4).
DISCUSSION
Our key observations from this study are as follows:
1. There was a large beneficial effect of apomor-
phine infusion on the whole of NMSS observed
along over one year average follow-up (Tables 2
and 3).
2. Patients with visual hallucinations, illusions and
paranoid ideations reported no worsening after
apomorphine infusion.
3. Apomorphine infusion resulted in significant
improvement in some specific NMS such as
hyperhidrosis, nocturia, urgency of micturition,
and fatigue.
Our “real life” study included patients who may
be excluded in randomised clinical trials and so we
used a pragmatic post-treatment surveillance method.
The follow-up period is therefore variable as clinical
appointments were based on the discretion of the clin-
icians or local arrangement methods as also reported
Table 2
Change in the items of Non-Motor Symptoms Scale (Apomorphine infusion group)
Items & Domains Baseline Follow-up p*
Cardiovascular
1 Light-headedness 3.53 ± 3.98 2.29 ± 3.06 0.03
2 Fainting 1.23 ± 2.63 0.47 ± 0.94 0.27
Sleep/Fatigue
3 Daytime sleeping 4.12 ± 4.44 2.88 ± 2.82 0.06
4 Fatigue 7.29 ± 3.93 2.82 ± 2.86 0.0004†
5 Difficult falling asleep 5.12 ± 5.04 2.47 ± 3.22 0.008†
6 Restless legs 5.53 ± 4.02 2.53 ± 3.54 0.003†
Mood/Cognition
7 Lost interest surroundings 2.94 ± 4.25 0.82 ± 2.13 0.009†
8 Lack motivation 3.65 ± 4.26 1.18 ± 1.74 0.009†
9 Nervous 6.12 ± 5.43 3.23 ± 3.47 0.003†
10 Sad 5.53 ± 4.98 2.88 ± 3.71 0.001†
11 Flat mood 2.23 ± 2.93 1.47 ± 2.87 0.09
12 Difficult experiencing pleasure 2.76 ± 4.38 1.71 ± 3.22 0.015†
Perceptual problems
13 Hallucinations 1.41 ± 2.45 0.53 ± 1.12 0.09
14 Delusions 1.53 ± 2.72 1.00 ± 1.87 0.3
15 Double vision 1.65 ± 3.26 0.35 ± 1.06 0.08
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Table 2
(Continued)
Items & Domains Baseline Follow-up p*
Cardiovascular
Attention/Memory
16 Problems with concentration 5.47 ± 4.49 3.29 ± 3.69 0.002†
17 Forget recent events 4.06 ± 3.53 2.88 ± 2.59 0.1
18 Forget doing things 3.29 ± 3.51 2.53 ± 2.65 0.2
Gastrointestinal
19 Dribbling saliva 2.23 ± 2.36 1.35 ± 1.97 0.015†
20 Swallowing 2.00 ± 2.52 1.00 ± 1.58 0.026
21 Constipation 3.12 ± 4.03 2.06 ± 3.44 0.026
Urinary
22 Urgency 3.71 ± 3.88 1.88 ± 2.87 0.005†
23 Frequency 2.59 ± 3.00 1.41 ± 3.32 0.015†
24 Nocturia 4.41 ± 3.78 2.41 ± 2.67 0.005†
Sexual function
25 Altered interest in sex 1.59 ± 3.41 0.82 ± 1.74 0.05
26 Problems having sex 0.94 ± 3.01 1.18 ± 2.65 0.5
Miscellaneous
27 Unexplained pains 1.76 ± 3.99 2.59 ± 4.11 0.6
28 Lost taste/smell 4.41 ± 4.27 3.41 ± 4.18 0.05
29 Change in weight 3.00 ± 4.55 1.29 ± 2.23 0.05
30 Excessive sweating 7.59 ± 4.43 3.23 ± 3.77 0.001†
*Wilcoxon test; †Significant after Benjamini-Hochberg correction, p < 0.025.
from a large multicentre study of apomorphine infusion
[8].
Apomorphine demonstrated benefit with a moderate
to large effect size in all domains of NMSS (Table 3)
along with UPDRS and PDQ-8. These data for the
first time indicate efficacy of apomorphine infusion on
NMS and improvement in HRQoL similar to the effect
of intra-jejunal levodopa gel infusion in advanced PD
as shown in a previous report from our group [28]. The
NNT confirmed a beneficial effect for most patients,
both for motor and non-motor manifestations (Table 4).
We also report non-worsening of the perceptual and
attention domain of NMSS (Tables 2 and 3) following
apomorphine, contrary to what is to be expected with
the use of a potent dopamine agonist in advanced PD.
Apomorphine may have a psychotropic action based on
its constituent anti-psychotic piperidine moiety [2, 3,
7, 29]. Improvement of psychosis was reported in 1978
in a placebo controlled study of apomorphine in 18
chronic schizophrenic patients [30]. In PD, open label
Table 3
Effect of the intervention (Apomorphine infusion grup) in relation to motor, non motor and quality of life measures
% of patients  FU–B Relative Effect Standardized
I NC W change Size Response Mean
UPDRS-Motor exam 100 0 0 –21.6 (9.56) –58.44 1.89 2.26
UPDRS-Complications 94 6 0 –6.47 (4.91) –64.70 1.01 1.32
NMSS-Cardiovascular 29 71 0 –1.88 (3.71) –40.86 0.33 0.51
Sleep 100 0 0 –11.35 (6.93) –51.45 0.99 1.64
Mood/apathy 82 18 0 –11.47 (10.90) –50.39 0.58 1.05
Perceptual 41 53 6 –2.71 (5.19) –59.04 0.39 0.52
Attention 71 23 6 –4.12 (7.31) –32.14 0.43 0.56
Gastrointestinal 59 41 0 –2.94 (3.77) –40.00 0.40 0.78
Urinary 71 29 0 –5.00 (5.26) –46.70 0.56 0.95
Sexual 82 6 12 –0.53 (2.50) –20.95 0.78 1.12
Miscellany 94 6 0 –9.00 (10.80) –48.73 0.62 0.83
NMSS-Total score 100 0 0 –49.00 (36.62) –46.25 0.75 1.34
PDQ-8 94 0 6 –23.34 (17.75) –41.92 1.18 1.31
UPDRS: Unified Parkinson’s Disease Rating Scale.
NMSS: Non-Motor Symptoms Scale; PDQ-8: Parkinson’s Disease Questionnaire-8 items; I: Improved; NC: No changed; W: Worsened;  FU–B:
Difference follow-up – baseline; mean (SD); For Effect size and Standardized Response Mean: 0.20–0.49, “small” effect; 0.50–0.79, “moderate”
effect; and ≥0.80, “large” effect.
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Table 4
NNT in patients treated with Apomorphine
SEM % of patients NNT
improving >1 SEM
UPDRS-Motor exam 10.48 82.35 1.21
UPDRS-Complications 5.34 47.06 2.12
NMSS- Cardiovascular 3.33 23.53 4.25
Sleep 8.11 58.52 1.71
Mood/apathy 11.74 41.18 2.43
Perceptual 4.89 17.65 5.67
Attention 6.08 29.41 3.40
Gastrointestinal 3.68 29.41 3.40
Urinary 5.21 35.29 2.83
Sexual 2.06 11.76 8.50
Miscellany 10.28 29.41 3.40
NMSS-Total score 42.40 52.94 1.90
PDQ-8 15.46 70.60 1.42
NNT = (1/% Improved) × 100; (n = 17).
studies had suggested safety of apomorphine infusion
in those with neuropsychiatric problems on oral ther-
apy [29, 31]. Tolerability of apomorphine infusion in
our study may also be partly due to a significant reduc-
tion in LDE and cessation of therapy with other oral
dopamine agonists, except the use of rotigotine patch
in some cases.
The NMSS has been validated in over 600 patients
and allows assessment of specific NMS within one
instrument [13, 14]. Using NMSS, we report signif-
icant beneficial effects on sleep disturbances such as
onset insomnia and restless legs while excessive day-
time sleepiness was not worsened. Other NMS effects
included a significant improvement in fatigue, motiva-
tion, anxiety, flat mood, anhedonia, attention deficit,
dribbling of saliva, urinary dysfunction, particularly
urgency and nocturia, and hyperhidrosis (Table 2).
Some of these NMS may have an underlying dopamin-
ergic basis while in others the improvements indicate
successful amelioration of subtypes of non-motor off
periods [32]. Our data also supports data from previous
open-label studies reporting a beneficial effect of apo-
morphine infusion on sleep (notably severe insomnia),
anhedonia and night time pain and cramps suggestive
of restless legs syndrome [11, 12, 29, 33].
This is not a randomised controlled study and we
do not have a true control group. However, data from
randomised controlled trials may occasionally have
limited external validity [34]. We studied small num-
ber of patients although by comparison, the only
other comparative study addressing apomorphine and
deep brain stimulation included 13/12 patients only
[35]. Similarly, the only comparative study of apo-
morphine versus levodopa infusion included 4 patients
only [36]. In our study, a moderate to large effect
of apomorphine was evident with the current sample
size.
In conclusion, this observational post-treatment
surveillance based study indicates the non-motor
effects of apomorphine infusion. Specific non-motor
effects of apomorphine are highlighted, calling for con-
trolled studies with non-motor primary endpoints.
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